Finance

Lists
Q1 2027 earnings • released • Revenue miss -0.23%
See results
NATCOPHARM:NSE
Natco Pharma Ltd
₹907.00
-4.70%
(-44.70) 1D
Aug 14, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for NATCOPHARM...
Open
₹951.70
High
₹964.85
Low
₹886.35
Mkt. cap
161.70B
Avg. vol.
0.00
Volume
2.49M
Dividend
0.55%
Quarterly dividend
₹1.25
Ex-dividend date
Feb 18, 2026
P/E ratio
11.45
52-wk high
₹1,226.80
52-wk low
₹789.00
EPS
₹79.20
Shares outstanding
182.26M
No. of employees
4K
Open
₹951.70
High
₹964.85
Low
₹886.35
Mkt. cap
161.70B
Avg. vol.
0.00
Volume
2.49M
Dividend
0.55%
Quarterly dividend
₹1.25
Ex-dividend date
Feb 18, 2026
P/E ratio
11.45
52-wk high
₹1,226.80
52-wk low
₹789.00
EPS
₹79.20
Shares outstanding
182.26M
No. of employees
4K
News stories
From web sources and news partners
Profile
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices. Wikipedia
About Natco Pharma Ltd
CEORajeev Nannapaneni
Employees4.2K
Founded1981
HeadquartersBanjara Hills, Telangana, India
SectorPharmaceutical industry
Websitenatcopharma.co.in
Last report
Aug 14, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
- / ₹8.86
Revenue / Est. (INR)
7.94B / 7.96B
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.63B
6.47B
7.39B
7.94B
Cost of goods sold
1.70B
1.33B
1.55B
1.48B
Cost of revenue
1.70B
1.33B
1.55B
1.48B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.00B
1.59B
1.58B
1.79B
Operating expense
6.66B
4.02B
5.07B
4.48B
Total operating expenses
8.36B
5.35B
6.62B
5.96B
Operating income
5.27B
1.12B
772.00M
1.99B
Other non operating income
1.00B
581.00M
778.00M
-
EBT including unusual items
6.14B
1.72B
1.80B
2.70B
EBT excluding unusual items
6.14B
1.72B
1.80B
2.70B
Income tax expense
958.00M
207.00M
-892.00M
634.00M
Effective tax rate
15.61%
12.03%
-49.61%
23.49%
Other operating expenses
4.14B
1.96B
2.98B
2.22B
Net income
5.18B
1.52B
2.68B
2.06B
Net profit margin
38.03%
23.40%
36.25%
25.99%
Earnings per share
28.94
8.46
14.96
-
Interest and investment income
-
-
-
-
Interest expense
-131.00M
-95.00M
-109.00M
-130.00M
Net interest expenses
-131.00M
-95.00M
-109.00M
-130.00M
Depreciation and amortization charges
524.00M
462.00M
504.00M
471.00M
EBITDA
5.82B
1.57B
1.29B
2.50B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps